Need professional-grade analysis? Visit stockanalysis.com
$79.37M
583.64
N/A
N/A
Seres Therapeutics Inc (MCRB) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $8.44, down 0.71% from the previous close.
Over the past year, MCRB has traded between a low of $6.77 and a high of $28.63. The stock has lost 7.0% over this period. It is currently 70.5% below its 52-week high.
Seres Therapeutics Inc has a market capitalization of $79.37M, with a price-to-earnings ratio of 583.64.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Side-by-side comparison against top Healthcare peers.